Takeda Pharmaceutical Company Limited (TYO:4502)
4,372.00
-71.00 (-1.60%)
Nov 17, 2025, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.11T JPY in the quarter ending September 30, 2025, a decrease of -5.38%. This brings the company's revenue in the last twelve months to 4.42T, down -2.84% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.42T
Revenue Growth
-2.84%
P/S Ratio
1.59
Revenue / Employee
93.08M
Employees
47,455
Market Cap
7.02T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |
| Eisai | 804.39B |
Takeda Pharmaceutical Company News
- 5 days ago - Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga
- 9 days ago - Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy - Nasdaq
- 9 days ago - Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy - Business Wire
- 14 days ago - New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization - Business Wire
- 17 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga
- 18 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga